PPARG and familial pancreatic carcinoma: In the present study, we investigated whether the PPARγ agonist, TGZ, exhibited in vitro cytotoxicity against two human pancreatic cancer cell lines, and clarified its mechanisms in terms of PPARγ dependency, apoptosis, and the mitogen-activated protein kinase (MAPK) pathway.